Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease.

Babić M, Svob Štrac D, Mück-Šeler D, Pivac N, Stanić G, Hof PR, Simić G.

Croat Med J. 2014 Aug 28;55(4):347-65. Review.

2.

The application of cerebrospinal fluid biomarkers in early diagnosis of Alzheimer disease.

Blennow K, Zetterberg H.

Med Clin North Am. 2013 May;97(3):369-76. doi: 10.1016/j.mcna.2012.12.012. Epub 2013 Feb 1. Review.

PMID:
23642576
3.

Proteomic analysis of cerebrospinal fluid in Alzheimer's disease: wanted dead or alive.

Oláh Z, Kálmán J, Tóth ME, Zvara Á, Sántha M, Ivitz E, Janka Z, Pákáski M.

J Alzheimers Dis. 2015;44(4):1303-12. doi: 10.3233/JAD-140141.

PMID:
25428253
4.

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease.

Blennow K, Hampel H, Weiner M, Zetterberg H.

Nat Rev Neurol. 2010 Mar;6(3):131-44. doi: 10.1038/nrneurol.2010.4. Epub 2010 Feb 16. Review.

PMID:
20157306
5.

Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.

Sutphen CL, Jasielec MS, Shah AR, Macy EM, Xiong C, Vlassenko AG, Benzinger TL, Stoops EE, Vanderstichele HM, Brix B, Darby HD, Vandijck ML, Ladenson JH, Morris JC, Holtzman DM, Fagan AM.

JAMA Neurol. 2015 Sep;72(9):1029-42. doi: 10.1001/jamaneurol.2015.1285.

6.

Biomarkers in the Diagnosis and Prognosis of Alzheimer's Disease.

Schaffer C, Sarad N, DeCrumpe A, Goswami D, Herrmann S, Morales J, Patel P, Osborne J.

J Lab Autom. 2015 Oct;20(5):589-600. doi: 10.1177/2211068214559979. Epub 2014 Nov 25. Review.

PMID:
25424384
7.

[Biomarkers in Alzheimer's disease].

García-Ribas G, López-Sendón Moreno JL, García-Caldentey J.

Rev Neurol. 2014 Apr 1;58(7):308-17. Review. Spanish.

8.

Fluid biomarkers in Alzheimer disease.

Blennow K, Zetterberg H, Fagan AM.

Cold Spring Harb Perspect Med. 2012 Sep 1;2(9):a006221. doi: 10.1101/cshperspect.a006221. Review.

9.

Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.

Lautner R, Palmqvist S, Mattsson N, Andreasson U, Wallin A, Pålsson E, Jakobsson J, Herukka SK, Owenius R, Olsson B, Hampel H, Rujescu D, Ewers M, Landén M, Minthon L, Blennow K, Zetterberg H, Hansson O; Alzheimer’s Disease Neuroimaging Initiative.

JAMA Psychiatry. 2014 Oct;71(10):1183-91. doi: 10.1001/jamapsychiatry.2014.1060.

PMID:
25162367
10.

YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease.

Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, Cairns NJ, Mintun MA, Peskind ER, Li G, Galasko DR, Clark CM, Quinn JF, D'Angelo G, Malone JP, Townsend RR, Morris JC, Fagan AM, Holtzman DM.

Biol Psychiatry. 2010 Nov 15;68(10):903-12. doi: 10.1016/j.biopsych.2010.08.025. Erratum in: Biol Psychiatry. 2011 Feb 15;69(4):389.

11.

Fluid biomarkers in Alzheimer's disease - current concepts.

Rosén C, Hansson O, Blennow K, Zetterberg H.

Mol Neurodegener. 2013 Jun 21;8:20. doi: 10.1186/1750-1326-8-20. Review.

12.

Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.

Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O.

Arch Gen Psychiatry. 2012 Jan;69(1):98-106. doi: 10.1001/archgenpsychiatry.2011.155.

PMID:
22213792
13.

Amyloid beta 1-42 and tau in the cerebrospinal fluid of renal failure patients for the diagnosis of Alzheimer's disease.

Shea YF, Chu LW, Mok MY, Lam MF.

J Nephrol. 2014 Apr;27(2):217-20. doi: 10.1007/s40620-014-0043-6. Epub 2014 Jan 29.

PMID:
24473733
14.

CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease.

Blennow K, Vanmechelen E, Hampel H.

Mol Neurobiol. 2001 Aug-Dec;24(1-3):87-97. Review.

PMID:
11831556
15.

Plasma Proteomic Profiles of Cerebrospinal Fluid-Defined Alzheimer's Disease Pathology in Older Adults.

Dayon L, Wojcik J, Núñez Galindo A, Corthésy J, Cominetti O, Oikonomidi A, Henry H, Migliavacca E, Bowman GL, Popp J.

J Alzheimers Dis. 2017;60(4):1641-1652. doi: 10.3233/JAD-170426.

16.

Comprehensive Quantitative Profiling of Tau and Phosphorylated Tau Peptides in Cerebrospinal Fluid by Mass Spectrometry Provides New Biomarker Candidates.

Russell CL, Mitra V, Hansson K, Blennow K, Gobom J, Zetterberg H, Hiltunen M, Ward M, Pike I.

J Alzheimers Dis. 2017;55(1):303-313.

PMID:
27636850
17.

Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease.

Sunderland T, Linker G, Mirza N, Putnam KT, Friedman DL, Kimmel LH, Bergeson J, Manetti GJ, Zimmermann M, Tang B, Bartko JJ, Cohen RM.

JAMA. 2003 Apr 23-30;289(16):2094-103. Erratum in: JAMA. 2007 Oct 3;298(13):1516.

PMID:
12709467
18.

Role of CSF biomarkers in the diagnosis of prodromal Alzheimer's disease.

Parnetti L, Chiasserini D.

Biomark Med. 2011 Aug;5(4):479-84. doi: 10.2217/bmm.11.48. Review.

PMID:
21861669
19.

Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease.

Tarawneh R, D'Angelo G, Macy E, Xiong C, Carter D, Cairns NJ, Fagan AM, Head D, Mintun MA, Ladenson JH, Lee JM, Morris JC, Holtzman DM.

Ann Neurol. 2011 Aug;70(2):274-85. doi: 10.1002/ana.22448.

20.

Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease.

Tarawneh R, Head D, Allison S, Buckles V, Fagan AM, Ladenson JH, Morris JC, Holtzman DM.

JAMA Neurol. 2015 Jun;72(6):656-65. doi: 10.1001/jamaneurol.2015.0202.

Supplemental Content

Support Center